4 results match your criteria: "a National Heart and Lung Institute[Affiliation]"
Cell Adh Migr
June 2019
b INSERM, UMR1053, BaRITOn Bordeaux Research in Translational Oncology , Bordeaux , France.
Climacteric
August 2016
d Obstetrics and Gynaecology , Sydney Medical School North, University of Sydney, Sydney , Australia.
Cardiovascular disease is the leading cause of morbidity and mortality in postmenopausal women. Although it is a disease of aging, vascular disease initiates much earlier in life. Thus, there is a need to be aware of the potential to prevent the development of the disease from an early age and continue this surveillance throughout life.
View Article and Find Full Text PDFExpert Opin Pharmacother
June 2016
a National Heart and Lung Institute, Imperial College, London , UK.
Introduction: Therapies for cystic fibrosis (CF) pulmonary disease have, until recently, all targeted downstream manifestations rather than the root cause of the disease. A step-change in our approach has been achieved in the last few years, with novel small-molecule CFTR modulating drugs entering the clinic.
Areas Covered: In this article, we will discuss the field of drug development for CF lung disease.
Postgrad Med
April 1975
a National Heart and Lung Institute, Bethesda.